Cite
HARVARD Citation
Colombo, N. et al. (n.d.). 1002TiPBAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer. Annals of oncology. p. . [Online].